CAY10499: Precision Lipase Inhibition for Lipid Signaling Research

Introduction: The Critical Role of Lipase Inhibitors in Modern Research

Lipid metabolism underlies cellular energy balance, signaling, and disease progression. Human hormone sensitive lipase (HSL) and monoglyceride lipase (MGL) orchestrate the hydrolysis of triglycerides and monoacylglycerols, thereby modulating fatty acid mobilization, steroidogenesis, and endocannabinoid pathways. Inhibiting these enzymes with high specificity is essential for dissecting their distinct roles in both health and disease. CAY10499, a potent inhibitor of human hormone sensitive lipase and monoglyceride lipase, has emerged as a highly selective tool for researchers seeking to untangle these complex networks (source: product_spec).

Mechanism of Action: Selectivity and Potency of CAY10499

CAY10499 is a crystalline small molecule designed to selectively inhibit both HSL and MGL, two enzymes pivotal for lipid breakdown and signaling. It achieves full inhibition of recombinant human HSL with an IC₅₀ of 90 nM and potently blocks MGL-mediated hydrolysis of 4-nitrophenyl acetate with an IC₅₀ of 0.5 ± 0.03 μM (source: product_spec). Additionally, it inhibits FAAH-mediated [3H]-AEA hydrolysis with an IC₅₀ of 76 nM, yet shows minimal displacement of [3H]-CP-55940 binding to CB1 and CB2 receptors, underscoring its selectivity (source: product_spec).

This dual inhibition profile allows for the precise modulation of both glyceride and endocannabinoid pathways. HSL catalyzes the hydrolysis of tri-, di-, and monoacylglycerols and cholesterol esters, while MGL primarily regulates 2-arachidonoylglycerol (2-AG), a key endocannabinoid transmitter (source: product_spec). Such selectivity is invaluable in research settings where off-target effects compromise data integrity.

Reference Insight Extraction: EV-Transferred ACLY and the Lipid Signaling Axis

A landmark study recently uncovered that extracellular vesicles (EVs) derived from hepatocellular carcinoma (HCC) cells deliver ATP-citrate lyase (ACLY) to monocytes, driving their differentiation into tumor-associated macrophages (TAMs) with immunosuppressive features. Mechanistically, EV-encapsulated ACLY elevates palmitate biosynthesis, which in turn enhances palmitoylation and stability of immune checkpoint proteins, fueling tumor progression. Notably, targeting this EV-transferred ACLY modulated TAM function and improved immunotherapy outcomes (source: paper).

This finding is transformative because it links lipid metabolic remodeling—specifically, the citrate–palmitate axis—to immune cell fate within the tumor microenvironment. For researchers, it highlights the importance of dissecting not just classic lipid hydrolysis but also the interplay of lipid signaling and immune modulation. The study’s innovative use of CD81-decorated liposomal vesicles to selectively block TAM-specific ACLY exemplifies the utility of precise metabolic interventions in immunometabolic research.

Protocol Parameters

• assay: HSL inhibition assay | value_with_unit: IC₅₀ = 90 nM | applicability: Quantitative evaluation of lipase inhibitor potency in lipid metabolism studies | rationale: Enables selective inhibition of human recombinant HSL, minimizing off-target effects in lipid hydrolysis assays | source_type: product_spec
• assay: MGL hydrolysis inhibition (4-NPA substrate) | value_with_unit: IC₅₀ = 0.5 ± 0.03 μM | applicability: Discriminating MGL involvement in monoacylglycerol metabolism | rationale: Quantifies MGL-specific activity, facilitating endocannabinoid pathway research | source_type: product_spec
• assay: FAAH inhibition ([3H]-AEA hydrolysis) | value_with_unit: IC₅₀ = 76 nM | applicability: Controls for off-target effects in endocannabinoid signaling assays | rationale: Ensures FAAH-targeted experiments remain specific, with low cross-reactivity | source_type: product_spec
• assay: Solubility in DMSO | value_with_unit: ≥32.4 mg/mL | applicability: Preparation of high-concentration stock solutions for in vitro assays | rationale: Supports flexible assay design and reagent stability | source_type: product_spec
• assay: Solubility in ethanol | value_with_unit: ≥8.93 mg/mL | applicability: Alternative solvent system for reagent compatibility | rationale: Provides workflow alternatives when DMSO is unsuitable | source_type: product_spec
• assay: Storage temperature | value_with_unit: -20°C (solid) | applicability: Maximizes compound stability during long-term storage | rationale: Preserves crystalline integrity and potency | source_type: product_spec
• assay: Aqueous solubility | value_with_unit: insoluble | applicability: Not suitable for direct aqueous applications; requires organic solvent pre-dissolution | rationale: Guides workflow planning and solvent selection | source_type: product_spec
• assay: Short-term solution stability | value_with_unit: use solutions promptly | applicability: Avoids loss of activity in extended incubations | rationale: Ensures reproducibility and assay sensitivity | source_type: workflow_recommendation

Advanced Applications: Dissecting Lipid Signaling in Immunometabolism and Beyond

CAY10499’s unique dual-inhibition of HSL and MGL enables researchers to parse the respective contributions of neutral lipid hydrolysis and endocannabinoid signaling in complex biological systems. For instance, in the context of tumor immunology, lipid metabolism shapes macrophage polarization and immune checkpoint regulation, as elegantly demonstrated in recent ACLY-EV studies (source: paper).

Researchers investigating steroidogenesis or diabetes-related lipid flux can deploy CAY10499 as a highly selective inhibitor for steroidogenesis research and as an enzyme inhibitor for fatty acid mobilization studies. Its minimal activity at cannabinoid receptors ensures that observed effects on 2-AG metabolism and related pathways are not confounded by direct receptor antagonism, which is a significant advantage over less selective inhibitors (source: product_spec).

In atherosclerosis models, where foam cell formation and macrophage lipid loading are central, CAY10499 serves as a research tool for atherosclerosis by enabling the delineation of HSL- and MGL-dependent mechanisms without interference from non-specific lipid hydrolysis. This distinction is particularly valuable when contrasting with the metabolic rewiring seen in EV-mediated ACLY transfer and TAM differentiation (source: paper).

Comparative Analysis: CAY10499 Versus Alternative Lipid Metabolism Tools

While numerous lipase inhibitors exist, few match CAY10499’s dual potency and selectivity. For example, classic HSL inhibitors may lack MGL activity, limiting their utility in studies where both neutral glyceride and endocannabinoid pathways are implicated. Conversely, broad-spectrum inhibitors risk confounding off-target effects, particularly in cell-based assays.

Recent articles, such as "CAY10499: Reliable Inhibitor of Human Hormone Sensitive Lipase", emphasize practical troubleshooting and optimizing reproducibility in cellular assays. In contrast, this article provides a mechanistic and translational analysis, focusing on the molecular selectivity and cross-pathway implications of CAY10499. Similarly, while "Translating Lipid Hydrolysis Inhibition: CAY10499 in Modern TAM and Metabolic Research" bridges translational perspectives and the EV-ACLY axis, our discussion prioritizes the integration of recent mechanistic insights into practical assay design, especially regarding immune cell fate and metabolic flux. Finally, "CAY10499: Unlocking Lipid Metabolism Assays in Disease Research" provides an assay-oriented overview; our article deepens the discussion by connecting selectivity profiles with new immunometabolic paradigms.

Why This Cross-Domain Matters, Maturity, and Limitations

The intersection between lipid metabolism and immunology—exemplified by the EV-ACLY-TAM axis—demonstrates that enzymes like HSL and MGL are not isolated actors but critical nodes in broader signaling networks. Tools such as CAY10499 are thus indispensable for elucidating the metabolic underpinnings of immune cell differentiation and tumor microenvironment remodeling. However, while CAY10499 enables detailed study of hydrolytic pathways, it does not directly modulate upstream processes like citrate conversion or palmitoylation; thus, its utility is maximized when used in combination with other pathway-specific interventions (source: paper).

Researchers should also note that, as with any small molecule, off-target effects cannot be categorically excluded, and careful control experiments remain essential. The maturity of lipase inhibition as a research tool is well established in metabolic disease contexts, but its integration into immunometabolic and tumor microenvironment studies continues to evolve.

Conclusion and Future Outlook

CAY10499, offered by APExBIO, stands as a robust, selective inhibitor for dissecting the intertwined roles of HSL and MGL in metabolic and immunological research. Its high potency, selectivity, and controllable solubility profile make it uniquely suited for advanced lipid metabolism assay development and for probing the metabolic regulation of immune cells. As recent discoveries clarify the significance of lipid-driven immune modulation—such as the EV-ACLY-TAM paradigm—tools like CAY10499 will be increasingly vital for both mechanistic and translational research (source: paper).

Looking forward, the integration of precise lipid enzyme inhibitors with emerging immunotherapeutic strategies may offer new avenues for disease intervention, particularly in cancer and metabolic disorders. The continued refinement of assay protocols and the pairing of CAY10499 with complementary metabolic modulators promise to expand our capacity to interrogate and manipulate lipid signaling with unprecedented precision.